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Received March 16, 2016; accepted August 5, 2016AbstractBackground: Despite a rising incidence of inflammatory bowel disease (IBD) in Taiwan, the clinical presentation of IBDs in this population has
yet to be well characterized. Therefore, the aim of our study was to identify and describe the clinical features of gastrointestinal (GI)
complications and extraintestinal manifestations (EIMs) of IBDs in the Taiwanese population.
Methods: We conducted a retrospective study between 1998 and 2011, with relevant medical information extracted from the National Health
Insurance Research Database. The diagnoses of IBD, GI complications, and EIMs were defined from the health registry using the appropriate
International Classification of Diseases 9 codes.
Results: A total of 3153 patients with IBDs were identified: 611 with Crohn’s disease (CD) and 2542 with ulcerative colitis, with GI
complications and EIMs identified in 22.2% and 11.9% of cases, respectively. CD was associated with an increased incidence of intestinal fistula,
perforation, obstruction, peritonitis and perianal disease, and ulcerative colitis with benign neoplasm of the colon. Colorectal cancer developed in
0.35% of patients. Children with CD characteristically have more complex intestinal complications. The prevalence of EIMs was higher
in females and in CD, with peripheral arthritis identified as the most common EIMs, overall. The rate of major EIMs affecting the articular,
cutaneous, and visual systems was lower than the rate reported in Western countries.
Conclusion: Our study found that CD had a more complicated course, with a higher incidence of GI complications and EIMs. However, the
prevalence of intestinal complications, perianal disease, and major EIMs was less common than in Western countries. This study provided a
distinct clinical feature of IBD in Taiwan.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Inflammatory bowel disease (IBD) is a multifactorial dis-
order comprising two major disorders, ulcerative colitis (UC)
and Crohn’s disease (CD). Dysregulation of the immune
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).results in chronic, immune-mediated inflammation.1e3 IBD is
associated with several gastrointestinal (GI) symptoms that
can vary widely in severity of presentation, and can include
any or all of the following: abdominal pain, diarrhea, GI
bleeding, intestinal fistula, intra-abdominal abscess, and peri-
anal disease (PD).1 IBD can also present with a large number
of extraintestinal manifestations (EIMs),4 with the major
EIM symptoms involving the musculoskeletal, cutaneous,
hepatobiliary, and ocular systems.
Historically, although IBDs have commonly been found in
Western countries, they have remained a rare occurrence in
Asia. However, the incidence of IBDs in Japan, Hong Kong,nd extraintestinal manifestations of inflammatory bowel disease in Taiwan: A
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Taiwan, which shares similar regional and cultural character-
istics with these areas, has also experienced an increasing
incidence of IBD. A nationwide study in Taiwan revealed an
increase in the annual incidence of UC and CD of 0.58e1.07
and 0.17e0.27 per 105 inhabitants, respectively, from 1998 to
2010.8 Despite the increasing numbers of patients with IBD,
however, the current level of knowledge regarding IBD pre-
sentation and prevalence of associated EIMs in Taiwan is
limited.
The aim of our retrospective study was to conduct a
nationwide review of medical records of patients having
received a diagnosis of IBD between January 1998 and
December 2011, to evaluate the current state of IBDs in
Taiwan. The prevalence of GI complications and EIMs was
calculated to define the clinical features of IBD. A secondary
aim was to determine associations of clinical features with the
type of IBD, namely CD or UC; age of presentation; and sex.
2. Methods2.1. Data sourceTable 1
Prevalence of extraintestinal manifestations in Crohn’s disease and ulcerative
colitis in Taiwan.
Extraintestinal manifestations ICD-9-CM Crohn’s
disease
Ulcerative
colitis
pa
n (%) n (%)
Musculoskeletal diseases
Peripheral arthritis 713.1,
715.0e715.9
37 (6.1) 155 (6.1) >0.99
Ankylosing spondylitis 720 11 (1.8) 44 (1.7) >0.99This study was approved by the Institutional Review Board
of the Taipei Veterans General Hospital (TPEVGH IRB No.:
2015-10-008CC; Taipei, Taiwan). Medical data were extracted
from the National Health Insurance Research Database
(NHIRD) for the years 1998e2011. The National Health In-
surance (NHI) is a social health insurance system with almost
100% of Taiwanese citizen enrolled (i.e., 94.7% of the na-
tional population in 1998 and 99.9% in 2011).9 Approximately
23 million people are registered in the NHI system,10 with the
NHIRD providing a comprehensive health database including,
but not limited to, diagnostic codes, date of registration, sex,
birthday, and dates of hospitalization.Bone manifestations
Osteoporosis 733.0 14 (2.3) 40 (1.6) 0.2922.2. Study patients
Hepatobiliary diseases
Cholangitis 576.1 13 (2.1) 20 (0.8) 0.007
Pancreatic diseases
Pancreatitis 577.0, 577.1 12 (2.0) 17 (0.7) 0.006
Mucocutaneous diseases
Erythema nodosum 695.2 11 (1.8) 7 (0.3) <0.001
Pyoderma gangrenosum 686.0 0 (0) 11 (0.4) d
Blood & vascular diseases
Venous/arterial
thromboembolism
453,
453.2e453.9
444
9 (1.5) 18 (0.7) 0.072
Renal diseases
Glomerulonephritis 580, 581,
582, 583
8 (1.3) 22 (0.9) 0.434
Neurological diseases
Peripheral neuropathy 356.8 3 (0.5) 7 (0.3) 0.652IBDs are classified as catastrophic illnesses by the NHI, and
patients receive financial support to cover medical costs. To
receive a catastrophic illness certificate (CIC), the medical
data of patients with suspected IBD are thoroughly reviewed
by a gastroenterologist commissioned by the Bureau of the
NHI. Evaluation is based on thorough documentation of the
clinical course, laboratory tests, imaging studies, endoscopic
pictures, and pathological findings. Patients with a CIC with
International Classification of Diseases 9 (ICD-9) codes of 555
for CD and 556 for UC were identified for our study, and their
medical records, including outpatient and hospitalization re-
cords, were extracted from the database and reviewed.Ocular diseases
Iritis/uveitis 364.0e364.3 2 (0.3) 4 (0.2) 0.7272.3. Epidemiology and clinical presentations
Scleritis/episcleritis 379.0 1 (0.2) 2 (0.1) >0.99
Bronchopulmonary diseases
Bronchiectasis 494 0 (0) 13 (0.5) d
ICD-9-CM¼ International Classification of Diseases, Ninth Revision, Clinical
Modification.
a The p value is from Chi-square test.Annual incidence rates were calculated by dividing the
number of newly registered IBD patients in the CIC database
each year by the group at risk (per 100,000 persons). The
“at-risk” group consisted of the total inhabitants in Taiwan,Please cite this article in press as: Hsu Y-C, et al., Gastrointestinal complications a
population-based study, Journal of the Chinese Medical Association (2016), httpeach year between 1998 and 2011, according to the records of
the Department of Household Registration.9
The diagnosis of GI complications and EIMs was
confirmed by the associated ICD-9 code registered in the
outpatient and hospitalization records in NHIRD. GI compli-
cations associated with IBDs, defined as “complicated GI
presentations,” including intestinal lesions (abscess: 569.5;
fistula: 569.81; perforation: 569.83), intestinal obstructions
(560.X ), peritonitis (567.X ), PD (anal fissure: 565; anal fis-
tula: 565.1; perianal abscess: 566), and benign and malignant
neoplasm of colon (211.3), were identified. A series of EIMs
were identified and included in our analysis11 (associated ICD
codes are mentioned in Table 1). GI complications and EIMs
diagnosed before the registration of an IBD were excluded
from our analysis.2.4. Statistical analysisStatistical evaluation was conducted using the Chi-square
test, Fisher’s exact test, and Yates' correction or Pearson’s
Chi-square test, depending on the nature and distribution of
the data. All analyses were performed using the SPSS version
20.0 statistical package (SPSS Inc., Chicago, IL, USA), with
p< 0.05 determined to be statistically significant.nd extraintestinal manifestations of inflammatory bowel disease in Taiwan: A
://dx.doi.org/10.1016/j.jcma.2016.08.009
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Prevalence of gastrointestinal complications in Crohn’s disease and ulcerative
colitis in Taiwan.
a
3.1. Patient characteristics and incidenceAnatomic lesions ICD-9-CM Crohn’s
disease
Ulcerative
colitis
p
n (%) n (%)
Intestinal obstruction 560, 560.8,
560.9
109 (17.8) 140 (5.5) <0.001
Intestinal lesions 72 (11.8) 55 (2.2) <0.001
Fistula 569.81 48 (7.9) 17 (0.7) <0.001
Perforation 569.83 29 (4.7) 40 (1.6) <0.001
Abscess 569.5 12 (2.0) 6 (0.2) <0.001
Perianal disease 57 (9.3) 175 (6.9) 0.038
Anal fistula 565.1 34 (5.6) 75 (3.0) 0.002
Perianal abscess 566 26 (4.3) 86 (3.4) 0.355
Anal fissure 565 16 (2.6) 51 (2.0) 0.432
Peritonitis 567.2, 567.9 54 (8.8) 67 (2.6) <0.001
Benign neoplasm
of colon
211.3 25 (4.1) 161 (6.3) 0.036
Colorectal cancer 153.0e153.9
154.0e154.8
1 (0.4) 10 (0.2) 0.402
ICD-9-CM¼ International Classification of Diseases, Ninth Revision, Clinical
Modification.
a The p value is from the Chi-square test.A total of 3153 patients with IBDs, 611 with CD and 2542
with UC, were registered in the CIC database between January
1, 1998, and December 31, 2011 (Table 2). The incidence of
CD and UC was higher in men as compared with that in
women. The median age at registration was 36.6 years for CD
and 43.6 years for UC. Of newly registered patients with an
IBD, 62% were between 30 years and 60 years of age. The
median duration of follow-up was 64.3 months (range,
0.07e167.2 months).
The mean annual incidence of CD and UC, for the period of
1998e2011, was 0.19 (95% confidence interval, 0.15e0.23)
and 0.80 (95% confidence interval, 0.68e0.91) per 105 in-
habitants, respectively. The incidence of CD increased grad-
ually from 0.13/105 inhabitants in 1998 to 0.33/105 inhabitants
in 2011. The incidence of UC also increased from 0.51/105
inhabitants in 1998 to 0.84/105 inhabitants in 2011, with its
highest incidence rate of 1.10/105 inhabitants recorded in 2010
(Fig. 1).3.2. GI complicationsThe prevalence of GI complications of IBDs is summarized
in Table 3. Of all patients with an IBD, 699 (22.2%) presentedTable 2
Demographic characteristics of patients with IBD in Taiwan.
Crohn’s disease Ulcerative colitis IBD
n (%) n (%) n (%)
No. of patients 611 (19.4) 2542 (80.6) 3153 (100)
Male/female 411 (13.0)/
200 (6.4)
1551 (49.2)/
991 (31.4)
1962 (62.2)/
1191 (37.8)
Age (y) at registration
16 64 (10.5) 52 (2.0) 116 (3.7)
17e40 290 (47.5) 1001 (39.4) 1291 (40.9)
>40 257 (42.0) 1489 (58.6) 1746 (55.4)
IBD¼ inflammatory bowel disease.
Fig. 1. Annual incidence of CD and UC in Taiwan, from 1998 to 2011.
CD¼Crohn’s disease; UC¼ ulcerative colitis.
Please cite this article in press as: Hsu Y-C, et al., Gastrointestinal complications a
population-based study, Journal of the Chinese Medical Association (2016), http:with at least one GI complication. The prevalence of GI
complications was higher in patients with CD, compared with
UC (33.6% and 19.4%, respectively; p< 0.001), and in males,
compared with females (24.7% and 18.0%, respectively;
p< 0.001). Changes of GI complications with the duration of
follow-up are shown in Fig. 2. At 14 years of follow-up, UC
patients were found to have a steadily increasing prevalence of
GI complications, while CD patients were found to reach the
peak prevalence of GI complications at the 9th year and
thereafter reach a plateau.
Intestinal lesions, including abscesses, fistula, and perfora-
tion, were more common in patients with CD. However, it was
noted that age at CD onset affected the disease presentation.
Pediatric patients with CD registered before 16 years of agewere
at the highest risk for developing intestinal lesions, compared
with two other age groups (younger than 16 years, 17.2%;
17e40 years, 13.8%; older than 40 years, 8.2%; p¼ 0.04).
PDs, such as anal fissure, fistula, and perianal abscess, were
more common in patients with CD compared UC. The
occurrence of anal fistulas was significantly higher in patients
with CD, with a higher prevalence in males (7.1% and 3.9%,
respectively; p¼ 0.008). Benign neoplasms of the colon were
more frequent in patients with UC compared with those with
CD, with males, again, being at higher risk (7.0% and 4.1%,
respectively; p¼ 0.039).
A total of 11 patients, one with CD and 10 with UC, were
diagnosed with colorectal cancer (CRC), with the majority of
these patients being male (male, 9; female, 2). The overall
prevalence of CRC in patients with IBDs was 0.35%, with a
prevalence of 0.39% in patients with UC and 0.16% in patients
with CD. The median age of CRC diagnosis was 51.3 years in
patientswithUCand 66.7 years in patientswithCD. Themedian
duration of IBD prior to CRC diagnosis was 94.7 months in
patients with UC and 96.7 months in patients with CD.nd extraintestinal manifestations of inflammatory bowel disease in Taiwan: A
//dx.doi.org/10.1016/j.jcma.2016.08.009
Fig. 2. Change of the prevalence of GI complications and EIMs by CD and
UC patients over a 14-year follow-up period. CD¼Crohn’s disease;
EIM¼ extraintestinal manifestation; GI¼ gastrointestinal; UC¼ ulcerative
colitis.
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study group, EIMs were reported in 11.9% of cases (375 pa-
tients). Peripheral arthritis was the most common EIM re-
ported in both CD and UC patient groups. Overall, EIMs were
more frequently associated with CD, compared with UC
(14.9% and 11.2%, respectively; p¼ 0.011), with more
frequent presentation in females than in males (14.6% and
10.2%, respectively; p < 0.001). After 14 years of follow-up,
the prevalence of EIMs increased from 2.3% to 25.9% and
from 2.8% to 26.6% in patients with CD and UC, respectively
(Fig. 2). Among the major EIMs affecting the articular, cuta-
neous, biliary, and visual systems, the prevalence of peripheral
arthritis increased steadily throughout the follow-up period,
whereas that of other EIMs remains relatively constant
(Fig. 3).
Joint manifestations were comparable between CD and UC,
with the incidence of associated peripheral arthritis being
higher for females than for males in both groups (CD: 10.5%
and 3.9%, respectively, p¼ 0.002; UC: 7.9% and 5.0%,
respectively, p¼ 0.003). In the UC group, 11 (0.4%) patients
had pyoderma gangrenosum, with a higher incidence in fe-
males, compared with males (0.8% and 0.2%, respectively;
p¼ 0.034), with no cases identified in the CD group. ByPlease cite this article in press as: Hsu Y-C, et al., Gastrointestinal complications a
population-based study, Journal of the Chinese Medical Association (2016), httpcontrast, erythema nodosum was more commonly associated
with CD than with UC. Cholangitis, including primary scle-
rosing cholangitis (PSC), was diagnosed in 13 (2.1%) patients
with CD and 20 (0.8%) with UC. Pancreatitis was also more
frequently noted in CD than in UC. Other EIMs involving the
ocular, respiratory, renal, vascular, and neurological systems
appeared less frequently (Table 1). Generally, there was no
significant difference in the prevalence of these rare EIMs
between the CD and UC groups.
4. Discussion
Analyzing the large population-based IBD cohort, the pre-
sent study has three main findings. First, the incidence of IBD
in Taiwan increased almost two-fold from 1998 to 2011. Sec-
ond, patients with CD presented with more complex disease,
with more GI complications and EIMs. Third, age of IBD
presentation affected the development of GI complications, and
patients with an early onset of CD were at higher risk to have
complicated intestinal disease. Moreover, this retrospective
study represents comprehensive information about IBD pre-
sentation, useful for understanding the different manifestations
of these diseases in Taiwan and Western countries.
Owing to the characteristics of transmural inflammation in
CD, intestinal complications including stricture, fistula,
abscess, and perforation were more common in CD. Ramadas
et al12 reported an increase in the incidence of mucosal le-
sions, from 15% at the time of diagnosis to 32% at 5 years
post-diagnosis for strictures, and an increase from 4% to 23%
for penetrating mucosal lesions. The incidence of intestinal
lesions was relatively low in our study group, with an inci-
dence rate of 11.8% over a mean 5.8-year follow-up.
Previous studies have provided evidence that the develop-
ment of CD in children and adolescents is more severe and
extensive, compared with that in adults, often resulting in
significant intestinal complications, including strictures and
perforation.13,14 Our study also demonstrated a significantly
higher incidence of intestinal lesions among patients who
developed CD before 16 years of age. Therefore, age of onset
is a critical factor in estimating the rate of developing a
complex disease progression of CD.
PD in patients with IBD has usually been considered to be
related to CD. Our study also demonstrated the increasing
frequency of PD, especially anal fistula, in patients with CD.
In CD, anal fissures had been identified in 21e35% of cases
and abscesses, usually accompanied with fistulas, in 23e62%
of patients.15 Our study revealed a low incidence (10.5%) of
PD in patients with CD, similar to the findings of a study in
China in which PD was identified in only 5.6% of patients
with CD.16
The most common benign tumors in the colon are colo-
rectal polyps. In a general Taiwanese population, Wang et al17
reported a prevalence of 11.1% for hyperplastic polyps and
16.1% for adenomatous polyps. Our study demonstrated a
relatively low prevalence of colorectal polyps of 6.3% in
patients with UC and 4.1% in patients with CD. Kitiyakara
et al18 also found that only 4% of UC patients had dysplasticnd extraintestinal manifestations of inflammatory bowel disease in Taiwan: A
://dx.doi.org/10.1016/j.jcma.2016.08.009
Fig. 3. Change of the prevalence of major EIMs in patients with IBD over a 14-year follow-up period. EIM¼ extraintestinal manifestation; IBD¼ inflammatory
bowel disease.
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matous polyps. It is possible that the use of 5-aminosalicylic
acid in the treatment of IBDs may prevent the formation of
adenomas.
Patients with IBD are considered to be at increased risk for
CRC. A meta-analysis of 116 studies estimated the prevalence
of CRC in patients with UC to be 3.7% in Western countries.19
The annual incidence of CRC in patients with UC was re-
ported to range between 0.13% and 0.3%.19,20 The risk for
CRC in patients with CD was found to be similar to that in
patients with UC, and approximately two- to three-fold greater
than that in the general population.21 A series of studies in
Asia revealed a relatively low prevalence of UC-associated
CRC of 0.0e2.2%, which was comparable with the preva-
lence in our study.7
The reported prevalence of EIMs in patients with IBDs has
been reported to vary between 25% and 47% in Western
countries.7,22,23 By contrast, an overall lower rate of EIMs
(6e14%) have been reported in East Asia.24 Owing to dif-
ferences in the definition of EIMs, the true prevalence of EIMs
is difficult to define. In our study, we included only EIMs with
an immunological background and not with other symptoms
secondary to the complication of IBD. The overall prevalence
of EIMs in our study (11.9%) was similar to that reported in
East Asia, with a higher incidence among females and patients
with CD, comparable with previous studies.25
Two types of joint involvement are associated with IBD,
peripheral arthritis and axial arthropathy. A previous study of
1459 patients with IBDs reported a prevalence of peripheralPlease cite this article in press as: Hsu Y-C, et al., Gastrointestinal complications a
population-based study, Journal of the Chinese Medical Association (2016), http:arthritis of 10% in patients with CD and 6.1% in patients with
UC.26 Axial arthropathy was identified in 10e20% of patients
with IBD, and a final diagnosis of ankylosing spondylitis (AS)
in 2e10% of patients.27 Comparing the epidemiology of joint
involvement in IBD with that in previous studies, the preva-
lence of peripheral arthritis was relatively low in our study,
including a low occurrence of AS. However, the prevalence of
AS in patients with IBDs may be underestimated in Taiwan
due to the time required to fulfill the diagnostic criteria of AS.
We found that the prevalence of peripheral arthritis
increased from 1% to 15.4% after 14 years of follow-up. Palm
et al28 also described a three-fold increase of peripheral
arthritis after 6 years of IBD (3.5e12%), whereas Vavricka
et al29 found 46% and 17% patients with CD and UC,
respectively, developed peripheral arthritis after 30 years of
disease duration. “Gut synovial-axis” hypothesis may explain
the increasing rate of peripheral arthritis.30 Damage to the
intestinal epithelial cell leads to contact of the gut flora with
the antigen-presenting cells, thus activating innate immunity.31
As the disease course goes on, repeated exposure of microbial
antigens in the gut may trigger stronger immune response and
subsequent development of arthritis.
Pyoderma gangrenosum is a neutrophilic dermatosis and
often occurs in association with a systemic disease.32 Pyoderma
gangrenosum has been reported in 1e10% of patients with UC
and 1e2% of patients with CD, with a slight predilection for
females.33,34 Erythema nodosum is the most common cuta-
neous manifestation of IBD. In a cohort study of 2402 patients
in France, erythema nodosum was found to affect 5.6% ofnd extraintestinal manifestations of inflammatory bowel disease in Taiwan: A
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were identified in the association of erythema nodosum, pyo-
derma gangrenosum, and IBD.36 Our study revealed a low
prevalence of skin manifestation associated with both CD and
UC. The difference in genotypes between ethnic groups could
influence the clinical presentation of IBDs.
PSC is closely associated with IBD, particularly UC. In
Western countries, PSC is estimated to affect 2e7.5% of pa-
tients with IBD, with a lower prevalence in Asia
(0e1.7%).7,11,37 In our study, the diagnosis of PSC was based
on the ICD code 576.1. However, the ICD code 576.1 is not
specific to PSC, but rather includes a spectrum of cholangitis.
Therefore, evaluation of the prevalence of IBD-associated PSC
is limited to using the NHIRD. Further studies are needed to
investigate the clinical features of PSC in Taiwan.
In Taiwan, studies focusing on the clinical features of GI
complications and EIMs in patients with IBD are rare. A
single medical center-based study between 1988 and 2008
revealed EIMs in 4.5% of 406 UC patients.38 Any disparity
between Wei et al’s38 study and our report may be due to the
different inclusion criteria of EIMs and the patient number. In
the same study, Wei et al38 also found that colon cancer was
noted in six of 406 patients (1.5%), which was higher than that
in our study (0.2%). This may be because the patients in Wei
et al’s38 study were collected from a tertiary referral center,
with more complicated disease. Another study detailing the
clinical features of CD in Taiwan revealed that intra-
abdominal abscess and intestinal perforation were noted in
5.5% and 3.6%, respectively, of 110 patients with CD in the
same medical center between 1988 and 2008. The result cor-
responded to our report, which demonstrates that patients with
CD in Taiwan have a relatively benign disease course
compared with those in Western countries.
There are some limitations to this study. First, collected
information was derived from an administrative database,
using ICD-9 diagnosis code, and the accuracy of diagnoses
cannot be assessed fully. In order to maximize case ascer-
tainment, we included patients with IBD who were registered
in the CIC database. Second, age of registration in the data-
base may not represent the real age of disease onset in some
patients with IBD; there may have been a time lag in regis-
tration. Third, NHIRD lacked clinical symptoms and labora-
tory data. Therefore, further analyses by disease behavior,
activity in IBD, and the association with comorbidity could
not be demonstrated. However, even with these intrinsic lim-
itations of NHIRD, the information is comprehensive and
valuable regarding the presentation of IBD.
In conclusion, this is the first nationwide population-based
study focusing on the clinical features of IBD in Taiwan. Our
study revealed distinct differences in the epidemiology of GI
complications and EIMs associated with IBDs, compared with
rates reported in Western countries. Generally, the risk for GI
complications and EIMs was higher in patients with CD. The
prevalence of intestinal lesions, PD, and major EIMs affecting
the articular, cutaneous, and ocular systems was less common
than the prevalence reported in Western countries. Both ge-
netic and environmental differences may contribute to thesePlease cite this article in press as: Hsu Y-C, et al., Gastrointestinal complications a
population-based study, Journal of the Chinese Medical Association (2016), httpunique epidemiological differences between Taiwan and
Western countries. Age at disease presentation and sex also
affect the clinical presentation of IBDs. Future studies inves-
tigating other associated factors may help establish a predic-
tive model of the clinical course of IBDs in Taiwan.References
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